BioNTech SE plans to expand its global footprint to Asia with the establishment of its Regional Headquarters in Singapore. The company also plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s pipeline of mRNA-based product candidates, as well as a rapid response production capability for south east Asia to address potential pandemic threats.

The new mRNA manufacturing facility will leverage cutting-edge manufacturing and digital infrastructure to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The site will bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine. 

BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval. The Company anticipates that the site could be operational in 2023 and will create up to 80 jobs in Singapore.

“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.

This follows the establishment of its U.S. Headquarters in Cambridge, MA in 2020.